Voyager Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
VYGR$1.83-8.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(amounts in thousands)
| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| · · Year ended · | ||||||||||
| · · December 31, | ||||||||||
| · 2023 · 2022 · 2021 | ||||||||||
| Cash flow from operating activities · · · · · · · | ||||||||||
| Net income (loss) | | $132,330 | | $(46,408) | | $(71,197) | | |||
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | | | | | | | | | | |
| Stock-based compensation expense | | 11,153 | | | 9,344 | | | 11,324 | | |
| Depreciation | | 4,441 | | | 6,191 | | | 5,165 | | |
| Amortization of premiums and discounts on marketable securities | | | (3,626) | | | (16) | | | 349 | |
| Gain on lease termination | | | — | | | (2,468) | | | — | |
| Change in fair value of common stock and warrants to purchase equity securities | | | — | | | — | | | (2,460) | |
| Loss on disposal of fixed assets | | | 178 | | | 377 | | | — | |
| Changes in operating assets and liabilities: | | | | | | | | | | |
| Accounts receivable | | | (80,150) | | | — | | | — | |
| Related party collaboration receivable | | | (3,084) | | | 475 | | | 7,280 | |
| Prepaid expenses and other assets | | 76 | | | (1,967) | | | 1,883 | | |
| Operating lease, right-of-use assets | | | 1,975 | | | 3,462 | | | 2,606 | |
| Other non-current assets | | — | | | (152) | | | 69 | | |
| Accounts payable | | (962) | | | 1,992 | | | (60) | | |
| Accrued expenses | | 9,007 | | | (3,148) | | | (3,335) | | |
| Operating lease liabilities | | | (2,833) | | | (3,922) | | | (3,428) | |
| Deferred revenue | | | 9,414 | | | 23,731 | | | (1,721) | |
| Net cash provided by (used in) operating activities | | 77,919 | | (12,509) | | (53,525) | | |||
| Cash flow from investing activities | | | | | | | | | | |
| Purchases of property and equipment | | (3,256) | | (2,491) | | (1,609) | | |||
| Purchases of marketable securities | | (223,968) | | (54,848) | | (15,117) | | |||
| Proceeds from sales and maturities of marketable securities | | 85,581 | | 50,000 | | 82,632 | | |||
| Net cash (used in) provided by investing activities | | (141,643) | | (7,339) | | 65,906 | | |||
| Cash flow from financing activities | | | | | | | | | | |
| Proceeds from the exercise of stock options | | 1,852 | | 629 | | 28 | | |||
| Proceeds from the issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement | | | 31,121 | | | — | | | — | |
| Proceeds from the purchase of common stock under ESPP | | | 672 | | | 481 | | | 584 | |
| Net cash provided by financing activities | | 33,645 | | | 1,110 | | | 612 | | |
| Net (decrease) increase in cash and cash equivalents | | (30,079) | | (18,738) | | 12,993 | | |||
| Cash, cash equivalents, and restricted cash beginning of period | | 100,474 | | 119,212 | | 106,219 | | |||
| Cash, cash equivalents, and restricted cash end of period | | $70,395 | | $100,474 | | $119,212 | | |||
| Supplemental disclosure of cash and non-cash activities | | | | | | | | | | |
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | | $— | | $— | | $664 | | |||
| Capital expenditures incurred but not yet paid | | $— | | $14 | | $80 | | |||
VOYAGER THERAPEUTICS INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.